RT Journal Article SR Electronic T1 A Novel Autosomal Dominant Childhood-Onset Disorder Associated with Pathogenic Variants in VCP JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.06.19.23291232 DO 10.1101/2023.06.19.23291232 A1 Mah-Som, Annelise Y. A1 Daw, Jil A1 Huynh, Diana A1 Wu, Mengcheng A1 Creekmore, Benjamin C. A1 Burns, William A1 Skinner, Steven A. A1 Holla, Øystein L. A1 Smeland, Marie F. A1 Planes, Marc A1 Uguen, Kevin A1 Redon, Sylvia A1 Bierhals, Tatjana A1 Scholz, Tasja A1 Denecke, Jonas A1 Mensah, Martin A. A1 Sczakiel, Henrike L. A1 Tichy, Heidelis A1 Verheyen, Sarah A1 Blatterer, Jasmin A1 Schreiner, Elisabeth A1 Thies, Jenny A1 Lam, Christina A1 Spaeth, Christine A1 Pena, Loren A1 Ramsey, Keri A1 Narayanan, Vinodh A1 Seaver, Laurie H. A1 Rodriguez, Diana A1 Afenjar, Alexandra A1 Burglen, Lydie A1 Lee, Edward B. A1 Chou, Tsui-Fen A1 Weihl, Conrad C. A1 Shinawi, Marwan S. YR 2023 UL http://medrxiv.org/content/early/2023/06/22/2023.06.19.23291232.abstract AB Valosin-containing protein (VCP) is an AAA+ ATPase that plays critical roles in multiple ubiquitin-dependent cellular processes. Dominant pathogenic variants in VCP are associated with adult-onset multisystem proteinopathy (MSP) that presents with myopathy, bone disease, dementia, and/or motor neuron disease. Through GeneMatcher, we identified 13 unrelated individuals who carry novel heterozygous VCP variants (12 de novo, 1 inherited) associated with a childhood-onset disorder characterized by developmental delay, intellectual disability, hypotonia, and macrocephaly. Trio exome sequencing or multigene panel identified nine missense variants, two in-frame deletions, one frameshift, and one splicing variant. We performed in vitro functional studies and in silico modelling to investigate the impact of these variants on protein function. In contrast to MSP variants, most missense variants had decreased ATPase activity, and one caused hyperactivation. Other variants were predicted to cause haploinsufficiency, suggesting a loss-of-function mechanism. This is the first description of VCP-related neurodevelopmental disease presenting in childhood.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Washington University in St. Louis gave ethical approval for this work. IRB of Seattle Children's Hospital gave ethical approval for this work. IRB of WCG gave ethical approval for this work (Protocol #20120789). IRB of Helen DeVos Children's Hospital waived ethical approval for this work. IRB of Hospital Trousseau gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe, or the sequencing laboratory, have submitted these variants and associated phenotypes to ClinVar. Anonymized data will be shared by request from any qualified investigator.